In this edition of Archer’s Newsletter we highlight the Company’s first Multi-Project Wafer runs of a proof of concept biosensing graphene transistor for biochip integration.
Archer is transferring its first generation graphene field effect transistor design to a commercial foundry partner, following the completion of an optical lithography-compatible chip layout.
The recent progress in biochip development essentially advances the core sensing technology from concept to design. The Archer team has, in parallel, started discussions with potential global foundry partners for initial small production runs of graphene chip designs to evaluate product reliability.
We expect completed runs to arrive at the end of 2023 and I look forward to updating you on our progress towards foundry compatibility and scaled manufacture of Archer’s graphene-based sensors for biochip integration.
Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX: AXE)
Designed by Aaron Knight.